New research shows that bowel cancer may set its course very early through a “Big Bang” moment when tumor cells learn to evade the immune system. Normally, immune cells detect cancer via neoantigens, abnormal proteins on the cell surface. The study found that cancer cells can silence these warning signals right from the start through epigenetic changes, reducing neoantigen production and making tumors hard for the immune system to detect.
Once this immune-escape ability forms, it remains largely stable as the tumor grows, meaning the cancer’s interaction with the immune system is determined early. This insight could help predict which patients are likely to respond to immunotherapy, improving personalization since only about 15% currently benefit from these treatments.
The findings also point to new strategies: combining immunotherapy with drugs that reverse epigenetic silencing to restore neoantigen display, enhancing the immune system’s ability to recognize and kill cancer cells. This could improve outcomes for patients with advanced bowel cancer.